AIMMUNE THERAPEUTICS INC - COM (AIMT)

CUSIP: 00900T107

Q1 2018 13F Holders as of 31 Mar 2018

Type / Class
Equity / COM
Total 13F shares
46,414,550
Share change
+9,181,358
Total reported value
$1,475,382,616
Put/Call ratio
55%
Price per share
$31.83
Number of holders
148
Value change
+$290,333,730
Number of buys
97
Number of sells
43

Quarterly Holders Quick Answers

What is CUSIP 00900T107?
CUSIP 00900T107 identifies AIMT - AIMMUNE THERAPEUTICS INC - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of AIMMUNE THERAPEUTICS INC - COM (AIMT) as of Q1 2018

As of 31 Mar 2018, AIMMUNE THERAPEUTICS INC - COM (AIMT) was held by 148 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 46,414,550 shares. The largest 10 holders included PRICE T ROWE ASSOCIATES INC /MD/, Foresite Capital Management II, LLC, VANGUARD GROUP INC, BlackRock Inc., FMR LLC, Aisling Capital LLC, WELLINGTON MANAGEMENT GROUP LLP, STATE STREET CORP, EVENTIDE ASSET MANAGEMENT, LLC, and EAGLE ASSET MANAGEMENT INC. This page lists 148 institutional shareholders reporting positions in this security for the Q1 2018 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.